正肝化症汤加减配合西药治疗对原发性肝癌患者肝功能及T淋巴细胞亚群的影响

doi:10.3969/j.issn.1001-8131.2024.04.034

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (717 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the application effect of the addition and subtraction of Zhenggan Huazheng Tang together with western medicines（Capecitabine+Lenvatinib mesylate+Oxaliplatin）in the treatment of patients with Primary Liver Cancer（PLC）.Methods 68 patients with PLC were retrospectively selected according to the matching principle for the study,they were divided into control group and observation group,with 34 cases in each group according to different treatment schemes.Among them,those who were treated with Capecitabine+Lenvartinib mesylate were included in the control group,and those who were treated with Zhenggan Huazheng Decoction plus Capecitabine+Lenvartinib mesylate were included in the observation group.Objective remission rates were compared between the two groups,as well as the levels of liver function indicators[alkaline phosphatase（ALP）,total bilirubin（TBIL）],T lymphocyte subsets（CD3+,CD4+/CD8+）,and tumor markers[vimentin（VIM）,alpha fetoprotein（AFP）,Golgi protein 73（GP73）]before treatment,after 2 and 4 courses of treatment,and the occurrence of toxic side effects was also compared between the two groups.Results The Objective remission rate of the observation group（64.71%）was higher than that of the control group（35.29%）（P<0.05）;after 2 and 4 courses of treatment,the levels of ALP and TBIL in the observation group were lower than those in the control group（P<0.05）;the levels of CD3+,CD4+/CD8+ in the observation group were higher than those in the control group after 2 and 4 courses of treatment（P<0.05）;the levels of VIM,AFP and GP73 in the observation group were lower than those in the control group after 2 and 4 courses of treatment（P<0.05）;compared with the control group,there was no significant difference in the incidence of various toxic and side effects in the observation group（P>0.05）.Conclusion Zhenggan Huazheng Decoction combined with Capecitabine+Lenvatinib mesylate in the treatment of PLC patients can effectively improve the Objective remission rate of the disease,reduce the damage of liver function and immune function,delay the progression of the disease,and is safe and reliable.

Key words： Zhenggan Huazheng Decoction Capecitabine Lenvatinib mesylate Liver function T- lymphocyte subsets Tumor markers

Received: 16 April 2024

PACS:

R735.7

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Wang Lidong
	Wang Binbin
	Duan Zheng
	Zhang Juan

Cite this article:

Wang Lidong,Wang Binbin,Duan Zheng, et al. Effects of the Addition and Subtraction of Zhenggan Huazheng Tang Together with Western Drug Therapy on Liver Function and T Lymphocyte Subpopulations in Patients with Primary Hepatocellular Carcinoma[J]. journal1, 2024, 44(4): 112-115.

URL:

http://www.hrbyybjb.org.cn/EN/10.3969/j.issn.1001-8131.2024.04.034 OR http://www.hrbyybjb.org.cn/EN/Y2024/V44/I4/112

[1] 袁云,徐国辉.XELOX方案治疗晚期原发性肝癌的效果及对血清肿瘤标志物水平的影响[J].解放军医药杂志,2017,29(6):44-47.
[2] 于欣欣. 奥沙利铂联合卡培他滨治疗晚期原发性肝癌的效果[J].临床合理用药杂志,2021,14(8):96-97.
[3] 王洪云. 甲磺酸仑伐替尼联合TACE治疗中晚期原发性肝癌的临床效果及安全性分析[J].中国医学创新,2020,17(31):6-9.
[4] 刘子铭,戴铭,王振常,等.疏肝调脾化瘀汤联合TACE治疗肝郁脾虚型原发性肝癌的回顾性分析[J].广西中医药大学学报,2023,26(5):1-6.
[5] 李屏,韦巍,李明芬,等.原发性肝癌的中医及中西医结合临床治疗研究进展[J].河北中医,2018,40(4):628-632.
[6] 彭珍,毛咏梅,郭亚楠,等.柴胡蚤休汤对原发性肝癌患者血清MMP-9、VEGF、IGF-2水平及MSCT检查情况的影响研究[J].长春中医药大学学报,2022,38(4):409-412.
[7] 邢明远,黄清云,苏乙花.正肝化症汤联合艾迪注射液对原发性肝癌患者肝功能的影响[J].世界中医药,2019,14(11):2983-2987.
[8] 李文,易爱芬,毋玥.柔肝化纤解毒方辅助治疗对原发性肝癌患者经导管动脉栓塞化疗术后中医证候及肝功能的影响[J].癌症进展,2022,20(8):859-861,864.
[9] 周林,肖康,夏建辉.八珍汤加减辅助治疗原发性肝癌疗效及对患者外周血Th17/Treg平衡和不良反应的影响[J].陕西中医,2023,44(9):1216-1219.
[10] PhilipRubin,JohnT Hansen.肿瘤TNM分期图谱[M].天津科技翻译出版公司,2011.
[11] 国家感染性疾病临床医学研究中心,北京医学会肝病学分会,中国老年学及老年医学学会转化医学分会.晚期原发性肝癌精细化诊疗管理专家共识(2023年版)[J].中华肝脏病杂志,2023,31(9):910-920.
[12] 中华人民共和国国家卫生健康委员会医政医管局.原发性肝癌诊疗规范(2019年版)[J].临床肝胆病杂志,2020,36(2):277-292.
[13] 白小林. 现代中医内科学[M].长春:吉林科学技术出版社,2012:345-349.
[14] 张萍,艾斌.实体瘤免疫治疗疗效评价标准[J].国际肿瘤学杂志,2016,43(11):848-851.
[15] 皋文君,刘砚燕,袁长蓉.国际肿瘤化疗药物不良反应评价系统——通用不良反应术语标准4.0版[J].肿瘤,2012,32(2):142-144.
[16] 高琰妍,沈家欢,金晓新,等.培元抗癌汤联合甲磺酸阿帕替尼片治疗晚期原发性肝癌脾虚血瘀型的疗效及对外周血免疫细胞和肿瘤标志物的影响[J].河北中医,2022,44(1):96-99.
[17] 郑元元,李良松,赵彪.培元抗癌汤联合针刺治疗中晚期肝癌气虚血瘀证的临床研究[J].国际中医中药杂志,2023,45(6):673-678.
[18] 王志远,卢立全,牛继华.血清AFP、AFP-L3、AFU、GP73联合检测对原发性肝癌的诊断价值[J].海南医学,2022,33(2):216-218.